Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines

Robert P. Baughman; Keith C. Meyer; Ian Nathanson; Luis Angel; Sangeeta M. Bhorade; Kevin M. Chan; Daniel Culver; Christopher G. Harrod; Mary S. Hayney; Kristen B. Highland; Andrew H. Limper; Herbert Patrick; Charlie Strange; Timothy Whelan

doi:10.1378/chest.12-1075

Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines

Robert P. Baughman^*, Keith C. Meyer, Ian Nathanson, Luis Angel, Sangeeta M. Bhorade, Kevin M. Chan, Daniel Culver, Christopher G. Harrod, Mary S. Hayney, Kristen B. Highland, Andrew H. Limper, Herbert Patrick, Charlie Strange, Timothy Whelan

^*Corresponding author for this work

Medicine, Pulmonary Division

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Original language	English (US)
Pages (from-to)	1284-1288
Number of pages	5
Journal	CHEST
Volume	142
Issue number	5
DOIs	https://doi.org/10.1378/chest.12-1075
State	Published - Nov 2012

Funding

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Baughman's institution (University of Cincinnati) has received grants for research in sarcoidosis and idiopathic pulmonary fibrosis from Actelion Pharmaceuticals Ltd; Celgene Corporation; Cephalon, Inc; Centocor Ortho Biotech, Inc; Gilead Sciences, Inc; and InterMune. Dr Hayney has received grant support from the University of Wisconsin and the National Institutes of Health. She serves on the speakers' bureau for Merck Vaccines. Dr Patrick received a travel stipend from Omneotech, Inc; owns stock in pharmaceutical/medical device companies, including Human Economics, Rite Aid Corp, Numec, and Hospira, Inc; and is a member of the speakers' bureau for Gilead Sciences, Inc. Dr Strange has received grant monies and salary support from the National Institutes of Health to study cyclophosphamide and mycophenolate mofetil in scleroderma. He has received grant monies and salary support from Centocor Ortho Biotech, Inc, for the study of ustekinumab and golimumab in sarcoidosis. He has been a consultant for AstraZeneca; Uptake Medical; PneumRx, Inc; Pulmonx; Aeris Therapeutics; Talecris Biotherapeutics, Inc; CSL Behring; Baxter; Gilead Sciences, Inc; MedImmune, LLC; and Actelion Pharmaceuticals Ltd in the past 3 years. For the past 3 years, he has received speakers' bureau income from AstraZeneca; Talecris Biotherapeutics, Inc; Gilead Sciences, Inc; Actelion Pharmaceuticals Ltd; and Pfizer, Inc, and from the France Foundation for InterMune on topics not related to the subject of this article. Dr Whelan has received research support from Actelion Pharmaceuticals Ltd; Celgene Corporation; Centocor Ortho Biotech, Inc; and InterMune. He has also received consultant fees from InterMune. His contributions to this article were free from potential conflicts of interest related to these activities. Drs Meyer, Nathanson, Angel, Bhorade, Chan, Culver, Highland, and Limper and Mr Harrod have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1378/chest.12-1075

Cite this

Baughman, R. P., Meyer, K. C., Nathanson, I., Angel, L., Bhorade, S. M., Chan, K. M., Culver, D., Harrod, C. G., Hayney, M. S., Highland, K. B., Limper, A. H., Patrick, H., Strange, C., & Whelan, T. (2012). Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST, 142(5), 1284-1288. https://doi.org/10.1378/chest.12-1075

@article{ec62bf5fc8d54514941226e49a8d1233,

title = "Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines",

author = "Baughman, {Robert P.} and Meyer, {Keith C.} and Ian Nathanson and Luis Angel and Bhorade, {Sangeeta M.} and Chan, {Kevin M.} and Daniel Culver and Harrod, {Christopher G.} and Hayney, {Mary S.} and Highland, {Kristen B.} and Limper, {Andrew H.} and Herbert Patrick and Charlie Strange and Timothy Whelan",

note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Baughman's institution (University of Cincinnati) has received grants for research in sarcoidosis and idiopathic pulmonary fibrosis from Actelion Pharmaceuticals Ltd; Celgene Corporation; Cephalon, Inc; Centocor Ortho Biotech, Inc; Gilead Sciences, Inc; and InterMune. Dr Hayney has received grant support from the University of Wisconsin and the National Institutes of Health. She serves on the speakers' bureau for Merck Vaccines. Dr Patrick received a travel stipend from Omneotech, Inc; owns stock in pharmaceutical/medical device companies, including Human Economics, Rite Aid Corp, Numec, and Hospira, Inc; and is a member of the speakers' bureau for Gilead Sciences, Inc. Dr Strange has received grant monies and salary support from the National Institutes of Health to study cyclophosphamide and mycophenolate mofetil in scleroderma. He has received grant monies and salary support from Centocor Ortho Biotech, Inc, for the study of ustekinumab and golimumab in sarcoidosis. He has been a consultant for AstraZeneca; Uptake Medical; PneumRx, Inc; Pulmonx; Aeris Therapeutics; Talecris Biotherapeutics, Inc; CSL Behring; Baxter; Gilead Sciences, Inc; MedImmune, LLC; and Actelion Pharmaceuticals Ltd in the past 3 years. For the past 3 years, he has received speakers' bureau income from AstraZeneca; Talecris Biotherapeutics, Inc; Gilead Sciences, Inc; Actelion Pharmaceuticals Ltd; and Pfizer, Inc, and from the France Foundation for InterMune on topics not related to the subject of this article. Dr Whelan has received research support from Actelion Pharmaceuticals Ltd; Celgene Corporation; Centocor Ortho Biotech, Inc; and InterMune. He has also received consultant fees from InterMune. His contributions to this article were free from potential conflicts of interest related to these activities. Drs Meyer, Nathanson, Angel, Bhorade, Chan, Culver, Highland, and Limper and Mr Harrod have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.",

year = "2012",

month = nov,

doi = "10.1378/chest.12-1075",

language = "English (US)",

volume = "142",

pages = "1284--1288",

journal = "CHEST",

issn = "0012-3692",

publisher = "Elsevier Inc.",

number = "5",

}

Baughman, RP, Meyer, KC, Nathanson, I, Angel, L, Bhorade, SM, Chan, KM, Culver, D, Harrod, CG, Hayney, MS, Highland, KB, Limper, AH, Patrick, H, Strange, C & Whelan, T 2012, 'Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines', CHEST, vol. 142, no. 5, pp. 1284-1288. https://doi.org/10.1378/chest.12-1075

Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. / Baughman, Robert P.; Meyer, Keith C.; Nathanson, Ian et al.
In: CHEST, Vol. 142, No. 5, 11.2012, p. 1284-1288.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients

T2 - American College of Chest Physicians evidence-based clinical practice guidelines

AU - Baughman, Robert P.

AU - Meyer, Keith C.

AU - Nathanson, Ian

AU - Angel, Luis

AU - Bhorade, Sangeeta M.

AU - Chan, Kevin M.

AU - Culver, Daniel

AU - Harrod, Christopher G.

AU - Hayney, Mary S.

AU - Highland, Kristen B.

AU - Limper, Andrew H.

AU - Patrick, Herbert

AU - Strange, Charlie

AU - Whelan, Timothy

N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Baughman's institution (University of Cincinnati) has received grants for research in sarcoidosis and idiopathic pulmonary fibrosis from Actelion Pharmaceuticals Ltd; Celgene Corporation; Cephalon, Inc; Centocor Ortho Biotech, Inc; Gilead Sciences, Inc; and InterMune. Dr Hayney has received grant support from the University of Wisconsin and the National Institutes of Health. She serves on the speakers' bureau for Merck Vaccines. Dr Patrick received a travel stipend from Omneotech, Inc; owns stock in pharmaceutical/medical device companies, including Human Economics, Rite Aid Corp, Numec, and Hospira, Inc; and is a member of the speakers' bureau for Gilead Sciences, Inc. Dr Strange has received grant monies and salary support from the National Institutes of Health to study cyclophosphamide and mycophenolate mofetil in scleroderma. He has received grant monies and salary support from Centocor Ortho Biotech, Inc, for the study of ustekinumab and golimumab in sarcoidosis. He has been a consultant for AstraZeneca; Uptake Medical; PneumRx, Inc; Pulmonx; Aeris Therapeutics; Talecris Biotherapeutics, Inc; CSL Behring; Baxter; Gilead Sciences, Inc; MedImmune, LLC; and Actelion Pharmaceuticals Ltd in the past 3 years. For the past 3 years, he has received speakers' bureau income from AstraZeneca; Talecris Biotherapeutics, Inc; Gilead Sciences, Inc; Actelion Pharmaceuticals Ltd; and Pfizer, Inc, and from the France Foundation for InterMune on topics not related to the subject of this article. Dr Whelan has received research support from Actelion Pharmaceuticals Ltd; Celgene Corporation; Centocor Ortho Biotech, Inc; and InterMune. He has also received consultant fees from InterMune. His contributions to this article were free from potential conflicts of interest related to these activities. Drs Meyer, Nathanson, Angel, Bhorade, Chan, Culver, Highland, and Limper and Mr Harrod have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

PY - 2012/11

Y1 - 2012/11

UR - http://www.scopus.com/inward/record.url?scp=84868610096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868610096&partnerID=8YFLogxK

U2 - 10.1378/chest.12-1075

DO - 10.1378/chest.12-1075

M3 - Article

C2 - 23131936

AN - SCOPUS:84868610096

SN - 0012-3692

VL - 142

SP - 1284

EP - 1288

JO - CHEST

JF - CHEST

IS - 5

ER -

Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this